BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, CD19-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPIES

Title:

BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, CD19-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPIES

Document Type and Number:

WIPO Patent Application WO/2019/099639

Kind Code:

A8

Abstract:

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.

More Like This:

JPH08500836	[Title of the Invention] Treatment of cancer with neurotrophic factors and cell proliferation inhibitors
WO/2022/105043	CONTROLLED-RELEASE DRUG FOR TREATING IMMUNE DISORDERS AND PREPARATION METHOD THEREFOR
JPH10509172	INDUSTRIAL APPLICABILITY A method for treating multiple sclerosis using a peptide analog of a human myelin basic protein.

Inventors:

GARFALL ALFRED (US)
COHEN ADAM (US)
MILONE MICHAEL (US)
PLESA GABRIELA (US)
STADTMAUER EDWARD (US)
JUNE CARL (US)

Application Number:

PCT/US2018/061239

Publication Date:

October 31, 2019

Filing Date:

November 15, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

NOVARTIS AG (CH)
UNIV PENNSYLVANIA (US)

International Classes:

A61K38/17; A61K31/675; A61K31/7076; A61K35/17; A61P35/02

Attorney, Agent or Firm:

COLLAZO, Diana, M. et al. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: ULTRASOUND APPARATUSES AND METHODS FOR FABRICATING ULTRASOUND DEVICES

Next Patent: HOSE CLAMP WITH SPRING LINER AND METHOD